Multicomponent nanoparticles as nonviral vectors for the treatment of fabry disease by gene therapy

Citations of this article
Mendeley users who have this article in their library.


Purpose: Gene-mediated enzyme replacement is a reasonable and highly promising approach for the treatment of Fabry disease (FD). The objective of the present study was to demonstrate the potential applications of solid lipid nanoparticle (SLN)-based nonviral vectors for the treatment of FD. Methods: SLNs containing the pR-M10-αGal A plasmid that encodes the α-Galactosidase A (α-Gal A) enzyme were prepared and their in vitro transfection effcacy was studied in Hep G2 cells. We also studied the cellular uptake of the vectors and the intracellular disposition of the plasmid. Results: The enzymatic activity of the cells treated with the vectors increased signifcantly relative to the untreated cells, regardless of the formulation assayed. When the SLNs were prepared with protamine or dextran and protamine, the activity of the α-Gal A enzyme by the transfected Hep G2 cells increased up to 12-fold compared to that of untreated cells. Conclusion: With this work we have revealed in Hep G2 cells the ability of a multicomponent system based on SLNs to act as effcient nonviral vectors to potentially correct low α-Gal A activity levels in FD with gene therapy. © 2012 Ruiz de Garibay et al, publisher and licensee Dove Medical Press Ltd.




Ruiz de Garibay, A. P., Delgado, D., del Pozo-Rodríguez, A., Solinís, M. Á., & Gascón, A. R. (2012). Multicomponent nanoparticles as nonviral vectors for the treatment of fabry disease by gene therapy. Drug Design, Development and Therapy, 6, 303–310.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free